Glycomimetics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Crescent Biopharma, Inc. (NASDAQ: CBIO) filed its Form 10-Q for the quarter ended June 30, 2026, detailing its financial performance and ongoing clinical development activities.
Crescent Biopharma, a preclinical-stage biotechnology company, reported significant operating losses for Q3 2025 while advancing its lead oncology programs CR-001, CR-002, and CR-003.
Crescent Biopharma, a preclinical-stage biotechnology company, reported a net loss of $21.8 million for Q2 2025 and $36.9 million for the first six months of 2025, while highlighting its strategic reverse recapitalization and focus on advancing its oncology pipeline, particularly lead program CR-001.
GlycoMimetics reports Q1 2025 results, highlighting a net loss and ongoing efforts to finalize a merger with Crescent Biopharma amidst concerns about its ability to continue as a going concern.
GlycoMimetics, Inc. has entered into a merger agreement with Crescent Biopharma, Inc., following a strategic review and significant workforce reduction, while also reporting its Q3 2024 financial results.
10-Q: GlycoMimetics Faces Uncertain Future After Uproleselan Trial Setback, Initiates Strategic Review
GlycoMimetics is conducting a strategic review of its business after a Phase 3 trial of its lead drug candidate, uproleselan, failed to meet its primary endpoint, leading to an 80% workforce reduction.
GlycoMimetics' first quarter 2024 results show a net loss of $10.7 million, and the company's pivotal Phase 3 trial for uproleselan did not meet its primary endpoint.